Skip to main content
Download PDF

Clobazam

Neurotherapeutics volume 4, pages 138–144 (2007)Cite this article

Summary

Catastrophic childhood epilepsies such as infantile spasms (IS), progressive myoclonic epilepsy, and Lennox-Gastaut syndrome (LGS) are rare but debilitating and frequently persist into adulthood. Early, targeted use of medications that have demonstrated efficacy in the management of LGS or its associated epilepsies may simplify the patient’s treatment regimen and reduce the incidence of adverse events. Key to the overall benefit to the patient is to maximize seizure control while minimizing adverse effects, especially behavioral and cognitive problems. Clobazam has demonstrated clinical benefit and has been administered safely in more than 50 European studies in which data were reported on greater than 3000 pediatric and adult patients with epilepsy, 300 of whom were diagnosed with LGS; therefore, its use is now being investigated in the U.S. This review will explore the use of clobazam in the treatment of epilepsy, particularly with regard to its potential benefit in LGS. Though not currently approved for use in the U.S., a program is underway to gain Food and Drug Administration approval for the treatment of pediatric and adult patients with refractory epilepsy, specifically in LGS. A phase 2 study will be completed in late 2006 to investigate the safety and efficacy of clobazam as adjunctive therapy in 68 pediatric and adult patients with LGS.

References

  1. Hauser WA, Annegeis JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia 1993;34: 453–468.

    PubMed  CAS  Article  Google Scholar 

  2. Beaumanoir A, Blume W. The Lennox-Gastaut Syndrome-symptomatology during the seizure disorder. In: Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, eds. Epileptic syndromes in infancy, childhood, and adolescence. 3rd ed. London: John Libbey & Co., Ltd; 2002: 113–135.

    Google Scholar 

  3. Markand ON. Lennox-Gastaut syndrome (childhood epileptic encephalopathy). J Clin Neurophysiol 2003;20: 426–441.

    PubMed  Article  Google Scholar 

  4. Crumrine PK. Lennox-Gastaut syndrome. J Child Neurol 2002;17(suppl 1): S70–75.

    PubMed  Article  Google Scholar 

  5. Wheless JW. Nonpharmacologic treatment of the catastrophic epilepsies of childhood. Epilepsia 2004;45(suppl 5): 17–22.

    PubMed  Article  Google Scholar 

  6. Data on file. Ovation Pharmaceuticals. Initial IND.

  7. Canadian Clobazam Cooperative Group. Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Epilepsia 1991;32: 407–416.

    Article  Google Scholar 

  8. Sugai K. Clobazam as a new antiepileptic drug and clorazepate dipotassium as an alternative antiepileptic drug in Japan. Epilepsia 2004;45(suppl 8): 20–25.

    PubMed  CAS  Article  Google Scholar 

  9. Meldrum BS, Horton RW. Anticonvulsant activity in photosensitive baboons, Papio-papio, of two new 1,5 benzodiazepines. Psychopharmacology (Berl) 1979;60: 277–280.

    CAS  Article  Google Scholar 

  10. Chapman AG, Horton RW, Meldrum BS. Anticonvulsant action of a 1,5-benzodiazepine, clobazam, in reflex epilepsy. Epilepsia 1978;19: 293–299.

    PubMed  CAS  Article  Google Scholar 

  11. Fielding S, Lal H. A review of the animal pharmacology of clobazam: an update. Drug Dev Res 1982;2(suppl 1): 17–21.

    Article  Google Scholar 

  12. Vogel HG, Hoffman I. Pharmacology of HR 376 (clobazam). Hoechst Aktiengesellschaft Pharma Research, Pharmacology. Nov 24, 1975. ND;5: 3–102 (Aug 8, 1980).

    Google Scholar 

  13. Nagato K, Komine I, Kitagawa H, Matsukawa K, Tanaka K, Sakaguchi T. Study on acute toxicity of l-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro,2-4-diketo-3H-1, 5-benzodiazepine (HR 376) in mice. Research Laboratory, Hoechst Japan Limited, Saitama-ken, Japan. June 13, 1974.

    Google Scholar 

  14. Schols DR, Schütz E. Report on an acute intraperitoneal test of HR 376 in mice. Pharmaceutical Research/Toxicology Farbwerke Hoechst AG. Nov 2, 1972d.

  15. Roell MG, Springman FR, Doerr BI. Acute oral toxicity of compound A 50 376 in mice. Hoechst Pharmaceutical Company, Sommerville, NJ. Mar 8, 1972a.

    Google Scholar 

  16. Nagato K, Komine I, Kitagawa H, Matsukawa K, Tanaka K, Sakaguchi T. Study on acute toxicity of 1-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro,2-4-diketo-3H-1, 5-benzodiazepine (HR 376) in rats. Research Laboratory, Hoechst Japan Limited, Saitama-ken, Japan. Nov 26, 1973.

    Google Scholar 

  17. Roell MG, Springman FR, Doerr BI. Acute intraperitoneal toxicity of compound A 50 376 in rats. Hoechst Pharmaceutical Company, Sommerville, NJ. Apr 4, 1972c.

    Google Scholar 

  18. Roell MG, Springman FR, Doerr BI. Acute oral toxicity of compound A 50 376 in rats. Hoechst Pharmaceutical Company, Sommerville, NJ. Mar 21, 1972b.

    Google Scholar 

  19. Hayashi S, Omosu M, Yajima R, Kobayashi T, Mizukami K, Sakaguchi T. Influence of the consecutive oral administration of l-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro,2-4-diketo-3H-1, 5-benzodiazepine (HR 376) to rats for 6 months. Pharmaceutical Laboratory, Hoechst Japan Limited, Saitama-ken, Japan. Feb 5, 1975.

    Google Scholar 

  20. Hayashi S, Omosu M, Kobayashi T, Mizukami K, Sakaguchi T. Influence of the consecutive oral administration of l-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro,2-4-diketo-3H-1, 5-benzodiazepine (HR 376) to rats for 28 days. Research Laboratory, Hoechst Japan Limited, Saitama-ken, Japan. Oct 4, 1974.

    Google Scholar 

  21. Doerr BI, Richardson E, Chesney CF. The chronic toxicity of compound A 50 376 when given to rats for eighteen months. Hoechst-Roussel Pharmaceuticals, Inc., Sommerville, NJ. Rep. No. 2171-H58. Aug 3, 1973.

    Google Scholar 

  22. Schols Dr, Schultes Dr. Report on an acute oral tolerance test of HR 376 in guinea pigs. Pharmaceutical Research/Toxicology Farbwerke Hoechst AG. Oct 24, 1972c.

  23. Roell MG, Springman FR, Doerr BI. Acute oral toxicity of compound A 50 376 in rabbits. Hoechst Pharmaceutical Company, Sommerville, NJ. May 18, 1972d.

    Google Scholar 

  24. Schols Dr, Schultes Dr. Report on an acute oral tolerance test of HR 376 dogs. Pharmaceutical Research/Toxicology Farbwerke Hoechst AG. Aug 30, 1972a.

  25. Schols Dr, Schültes Dr. Report on an oral exploratory tolerance test of HR 376 with repeated administration to dogs. Pharmaceutical Research/Toxicology Farbwerke Hoechst AG. Aug 30, 1972b.

  26. Springman FR, Roell MG, Doerr BI, Wolf GL. The chronic toxicity of compound A 50 376 when given orally to dogs for six months. Hoechst Pharmaceuticals, Inc., Sommerville, NJ. Rep. No.1971-H58. July 18, 1972.

    Google Scholar 

  27. Doerr BI, Richardson E, Willigan DA. The chronic toxicity of compound A 50 376 when given orally to dogs for one year. Hoechst-Roussel Pharmaceuticals, Inc., Sommerville, NJ. Rep. No. 2071-H58. Feb 20, 1974; revised Nov 13, 1974a.

    Google Scholar 

  28. Doerr BI, Richardson E, Chesney CF. The chronic toxicity of compound A 50 376 when given orally to dogs for one year. Hoechst-Roussel Pharmaceuticals, Inc., Sommerville, NJ. Rep. No. 0773-H58. Dec 23, 1974b.

    Google Scholar 

  29. Leuschner F, Leuschner A, Schwerdtfeger W, Kief H. Report on a chronic oral toxicity study of HR 376 (=A 50 376) (52 weeks) in rhesus monkeys. Laboratorium Fur Pharmakologie Und Toxikologie, Bredengrund. Sept 30, 1974.

    Google Scholar 

  30. Coulston F, Goldberg L, Rosenblum I, et al. A ten-week safety evaluation of A50376 in monkeys. Institute of Comparative and Human Toxicity, Albany Medical College, Albany, NY. Oct 1973.

    Google Scholar 

  31. McSheehy T, Cummins HA, Finn JP. RU 4723: oncogenic response in mice to dietary administration for 80 weeks. Life Science Research, Essex, England. Rep. No. 79/RUCO28/295. Oct 24, 1979a.

    Google Scholar 

  32. McSheehy T, Cummins HA, Finn JP. RU 4723: RU 4723: oncogenic response in rats to dietary administration for 104 weeks. Life Science Research, Essex, England. Rep. No. 79/RUCO27/367. Oct 24, 1979b.

    Google Scholar 

  33. Kramer M, Baeder C. Report on reproduction tests with HR 376 (A 50 376) in NMRI mice (influence on fertility, pregnancy and post-natal development) Farbwerke Hoechst AG. June 27, 1974.

  34. Baeder C, Scholz Dr. Report on reproduction test with HR 376 on Wistar rats (influence on fertility, pregnancy, post-natal development). Farbwerke Hoechst AG. Jan 29, 1973.

  35. Baeder C, Kramer M, Schutz E. Report on an oral peri- and post-natal toxicity study of HR 376 in Wistar rats. Hoechst Aktiengesellschaft Pharma Research, Radiochemistry. Sept 15, 1976.

  36. Vannier B, Glomot R. J. H 4723 teratology study. Department of Toxicology and Research Centre of Roussel-UCLAF, Romainville, France. July 10, 1972.

    Google Scholar 

  37. Krsmanovic L, Huston T. Mammalian erythrocyte micronucleus test, BioReliance study No.r AB06MT.123.BTL, draft report date Apr 25, 2005.

  38. Gudi R, Rao, M. In vitro mammalian chromosome aberration test. BioReliance study No. AB06MT.331.BTL; draft report date Apr 27, 2005.

  39. Wagner VO, Hines RM. Bacterial Reverse Mutation Assay. BioReliance Rep. No. AB06MT.503.BTL; draft report date Apr 14, 2005.

  40. Miyawaki, I., Moriyasu, M., Funabashi, H., Yasuba, M., Matsuoka, N. Mechanism of clobazam-induced thyroidal oncogenesis in male rats. Toxicol Lett 2003;145: 291–301.

    PubMed  CAS  Article  Google Scholar 

  41. Capen C. Development of benign follicular cell tumors (adenomas) following chronic administration of “clobazam” to Sprague-Dawley rats: specific and mechanistic comments, Feb 07, 2005.

  42. Rupp W, Badian M, Christ O, et al. Pharmacokinetics of single and multiple doses of clobazam in humans. Br J Clin Pharmacol 1979;7(suppl 1): 51S-57S.

    PubMed  Google Scholar 

  43. Davies IB, Pidgen AW, Mcween J, Robinson JD, Walker SE, Stonier Pd. Rectal absorption of clobazam: pharmacokinetic aspects and possible use in epilepsy. Clobazam: human psychopharmacology and clinical applications. R Soc Med Int Congr Symp Ser No 74;129–132.

  44. Divoll M, Greenblatt DJ, Ciraulo DA, Puri SK, Ho I, Shader RI. Clobazam kinetics: intrasubject variability and effect of food on adsorption. J Clin Pharmacol 1982;22: 69–73.

    PubMed  CAS  Google Scholar 

  45. Cenraud B, Guyot M, Levy RH, et al. No effect of food intake on clobazam absorption. Br J Clin Pharmacol 1983;16: 728–730.

    PubMed  CAS  Google Scholar 

  46. Tedeschi G, Riva R, Baruzzi A. Clobazam plasma concentrations: pharmacokinetic study in healthy volunteers and data in epileptic patients. Br J Clin Pharmacol 1981;11: 619–622.

    PubMed  CAS  Google Scholar 

  47. Farrell K. Benzodiazepines in the treatment of children with epilepsy. Epilepsia 1986;27(suppl 1): S45–52.

    PubMed  Article  Google Scholar 

  48. Dehnerdt M, Boenigk H, Rambeck B. Clobazam (Frisium) for the treatment of complications of epilepsy [in German]. In: Remschmidt H, Rentz R, Jungmann J, eds. Epilepsy 1980: psychological aspects, post-traumatic epilepsy, drug treatment, diagnostic methods. Meeting of the German Section of the International League Against Epilepsy in Berlin. Stuttgart: Georg Thieme; 1980: 172–175.

    Google Scholar 

  49. Bun H, Monjanel-Mouterde S, Noel F, Durand A, Cano JP. Effects of age and antiepileptic drugs on plasma levels and kinetics of clobazam and N-desmethylclobazam. Pharmacol Toxicol 1990;67: 136–140.

    PubMed  CAS  Article  Google Scholar 

  50. Giraud C, Tran A, Rey E, Vincent J, Treluyer JM, Pons G. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos 2004;32: 1279–1286.

    PubMed  CAS  Google Scholar 

  51. Contin M, Sangiorgi S, Riva R, Parmeggiani A, Albani F, Baruzzi A. Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam. Ther Drug Monit 2002;24: 737–741.

    PubMed  CAS  Article  Google Scholar 

  52. Bardy AH, Seppala T, Salokorpi T, Granstrom ML, Santavuori P. Monitoring of concentrations of clobazam and norclobazam in serum and saliva of children with epilepsy. Brain Dev 1991;13: 174–179.

    PubMed  CAS  Google Scholar 

  53. Grigoleit HG, Hajdu P, Hundt HK, et al. Pharmacokinetic aspects of the interaction between clobazam and cimetidine. Eur J Clin Pharmacol 1983;25: 139–142.

    PubMed  CAS  Article  Google Scholar 

  54. Mehndiratta MM, Krishnamurthy M, Rajesh KN, Singh G. Clobazam monotherapy in drug naive adult patients with epilepsy. Seizure 2003;12: 226–228.

    PubMed  CAS  Article  Google Scholar 

  55. Doi T, Ueda Y, Tokumaru J, Willmore LJ. Molecular regulation of glutamate and GABA transporter proteins by clobazam during epileptogenesis in Fe(+ + +)-induced epileptic rats. Brain Res Mol Brain Res 2005;142: 91–96.

    PubMed  CAS  Article  Google Scholar 

  56. Critchley EMR, Vakil SD, Hayward HW, Owen MV, Cocks A, Freemantle NP. Double-blind clinical study of clobazam in refractory epilepsy. In: Hindmarch I, Stonier PD, eds. Clobazam. R Soc Med Int Congr Symp Ser No 43:159–163

  57. Freche C. Study of an anxiolytic, clobazam, in otorhinolaryngology in psychosomatic pharyngeal manifestations [in French]. Sem Hop Ther 1975;51: 261–263.

    PubMed  CAS  Google Scholar 

  58. McKerman RM, Rosahl TW, Reynolds DS, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alphal subtype. Nat Neurosci 2000;3: 587–592.

    Article  Google Scholar 

  59. Nakajima H. A pharmacological profile of clobazam (Mystan), a new antiepileptic drug [in Japanese]. Nippon Yakurigaku Zasshi. 2001;118: 117–122.

    PubMed  CAS  Article  Google Scholar 

  60. Cano JP, Bun H, Iliadia A, Dravet C, Roger J, Gastaut H. Influence of anti-epileptic drugs on plasma levels of clobazam and desmethylclobazam: application of research on relations between doses, plasma levels, and clinical efficacy. In: Hindmarch I, Stonier PD, eds. Clobazam. R Soc Med Int Congr Symp Ser No 43:169–174

  61. Callaghan N, Goggin T. Clobazam as adjunctive treatment in drug resistant epilepsy—report on an open prospective study. Ir Med J. 1984;77: 240–244.

    PubMed  CAS  Google Scholar 

  62. Gastaut H. Exceptional and unrecognized antiepileptic properties of a commercial anxiolytic: clobazam [in French]. Concours Med 1978;100: 3697–3701.

    Google Scholar 

  63. Gastaut H, Low MD. Antiepileptic properties of clobazam, a 1–5 benzodiazepine, in man. Epilepsia 1979;20: 437–446.

    PubMed  CAS  Article  Google Scholar 

  64. Gastaut H. The effect of benzodiazepines on chronic epilepsy in man (with particular reference to clobazam). In: Hindmarch I, Stonier P, eds. Clobazam. R Soc Med Int Congr Symp Ser No 43:141–150.

  65. Vajda FJ, Bladin PF, Parsons BJ. Clinical experience with clobazam: a new 1,5 benzodiazepine in the treatment of refractory epilepsy. Clin Exp Neurol 1985;21: 177–182.

    PubMed  CAS  Google Scholar 

  66. Bravaccio F, D’Ambrosio G, De Rosa A, Tata MR, Volpe E. The anti-epileptic properties of a diazepine drug (clobazam). Preliminary results [in Italian]. Acta Neurol [Quad] (Napoli) 1979;39: 58–64.

    CAS  Google Scholar 

  67. Pechadre JC, Beudin P, Devoize JL, Gibert J. Anti-epileptic effect of clobazam in Lennox-Gastaut syndrome (author’s transl) [in French]. Encephale 1981;7: 181–190.

    PubMed  CAS  Google Scholar 

  68. Franceschi M, Ferini-Strambi L, Mastrangelo M, Smime S. Clobazam in drug-resistant and alcoholic withdrawal seizures. Clin Study J 1983;20: 119–125.

    Google Scholar 

  69. Guberman A, Couture M, Blaschuk K, Sherwin A. Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations. Can J Neurol Sci 1990;17: 311–316.

    PubMed  CAS  Google Scholar 

  70. Munn R, Farrell K. Open study of clobazam in refractory epilepsy. Pediatr Neurol 1993;9: 465–469.

    PubMed  CAS  Article  Google Scholar 

  71. Dalby MA. Clobazam in resistant epilepsy—a retrospective survey. In: Hindmarch I, Stoner PD, Trimble MR, eds. Clobazam: human psychopharmacology and clinical application. R Soc Med Int Congr Symp Ser No 74:189

  72. Bianchi A, Bellea A, Sideri G. Use of clobazam in epilepsy: experience gained from one year of treatment [in Italian]. Bolletino-Lega Italiana Contro L’Epilepssia 1980;29/30: 215–218.

    Google Scholar 

  73. Tondi M, Mattu B, Monaco F, Masia G. Electronical assessment of the antiepileptic effects of clobazam in children [in Italian]. Revista Italiana EEG Neurofisiologia Clinica 1980;3: 87–92.

    Google Scholar 

  74. Papini M, Pasquinelli A, Rossi L, et al. Preliminary report on the antiepileptic activity of clobazam [in Italian]. Revista Italiana EEG Neurofisiologia Clinica 1980;3: 93–98.

    Google Scholar 

  75. Figueroa D, Adlerstein L, Manterola A. Clobazam for refractory epilepsy in children [in Spanish]. Revista Chilena de Pediatria 1984;55: 401–405.

    PubMed  CAS  Google Scholar 

  76. Davila-Gutierrez G, Mondragon-Pineda A, Alcala-Negrete H. Usefulness of clobazam in the treatment of refractory epilepsy in children [in Spanish]. Bol Med Hosp Infant Mex 1990;47: 694–697.

    PubMed  CAS  Google Scholar 

  77. Jan MM, Shaabat AO. Clobazam for the treatment of intractable childhood epilepsy. Saudi Med J 2000;21: 622–624.

    PubMed  CAS  Google Scholar 

  78. Koeppen D, Baruzzi A, Capozza M, et al. Clobazam in therapy-resistant patients with partial epilepsy: a double-blind placebo-controlled crossover study. Epilepsia 1987;28: 495–506.

    PubMed  CAS  Article  Google Scholar 

  79. Dellaportas CI, Wilson A, Clifford RF. Clobazam as an adjunctive treatment in chronic epilepsy. In: Porter RJ, Mattson RH, Ward AA, Dam M, eds. Advances in epileptology: XVth Epilepsy International Symposium. New York: Raven Press; 1984: 363–367.

    Google Scholar 

  80. Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia 1998;39: 952–959.

    Article  Google Scholar 

  81. Wilson A, Dellaportas CI, Clifford RF. Low-dose clobazam as adjunctive therapy in chronic epilepsy. In: Hindmarch I, Stonier PD, Trimble MR, eds. Clobazam: human psychopharmacology and clinical application. R Soc Med Int Congr Symp Ser No 74:172–178

  82. Allen JW, Oxley J, Robertson MM, Trimble MR, Richens A, Jawad SS. Clobazam as adjunctive treatment in refractory epilepsy. Br Med J (Clin Res Ed) 1983;286: 1246–1247.

    CAS  Article  Google Scholar 

  83. Aucamp AK. Clobazam as adjunctive therapy in uncontrolled epileptic patients. Curr Ther Res Clin Exp 1985;37: 1098–1103.

    Google Scholar 

  84. Schmidt D, Rohde M, Wolf P, Roeder-Wanner U. Clobazam for refractory focal epilepsy. A controlled trial. Arch Neurol 1986;43: 824–826.

    PubMed  CAS  Google Scholar 

  85. Keene DL, Whiting S, Humphreys P. Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Can J Neurol Sci 1990;17: 317–319.

    PubMed  CAS  Google Scholar 

  86. Feely M, Calvert R, Gibson J. Clobazam in catamenial epilepsy. A model for evaluating anticonvulsants. Lancet 1982;2: 71–73.

    PubMed  CAS  Article  Google Scholar 

  87. Feely M, Gibson J. Intermittent clobazam for catamenial epilepsy: tolerance avoided. J Neurol Neurosurg Psychiatry 1984;47: 1279–1282.

    PubMed  CAS  Article  Google Scholar 

  88. Shimizu H, Kawasaki J, Yuasa S, Tarao Y, Kumagai S, Kanemoto K. Use of clobazam for the treatment of refractory complex partial seizures. Seizure 2003;12: 282–286.

    PubMed  Article  Google Scholar 

  89. Buchanan N, Sommerville E, Procopsis P. Clobazam in the treatment of epilepsy [abstract]. Clin Exp Pharmacol Physiol 1990; (suppl 16): Abstract 6.

  90. Sadler RM, Cohen B. Clobazaam in the treatment of partial complex seizures of probable temporal lobe origin [abstract]. Epilepsia 1992;33(suppl 3): 106.

    Google Scholar 

  91. Buchanan N. Clobazam in the treatment of epilepsy: prospective follow-up to 8 years. J R Soc Med 1993;86: 378–380.

    PubMed  CAS  Google Scholar 

  92. Heller AJ, Ring HA, Reynolds EH. Factors relating to dramatic response to clobazam therapy in refractory epilepsy. Epilepsy Res 1988;2: 276–280.

    PubMed  CAS  Article  Google Scholar 

  93. Munn R, Camfield P, Camfield C, Dooley J. Clobazam for refractory childhood seizure disorders—a valuable supplementary drug. Can J Neurol Sci 1988;15: 406–408.

    PubMed  CAS  Google Scholar 

  94. Kilpatrick C, Bury R, Fullinfaw R, Moulds R. Clobazam in the treatment of epilepsy. Clin Exp Neurol 1987;23: 139–144.

    PubMed  CAS  Google Scholar 

  95. Scott DF, Moffett A. Clobazam as an adjunctive therapy in chronic epilepsy: clinical, psychological, and EEG assessment. In: Hindmarch I, Stonier PD, Trimble MR, eds. Clobazam: human psychopharmacology and clinical application. R Soc Med Int Congr Symp Ser No 74: 181–187

  96. Scott DF, Moffett A. The long-term effect of clobazam as adjunctive therapy in epilepsy. Acta Neurol Scand. 1988;77: 498–502.

    PubMed  CAS  Article  Google Scholar 

  97. Wolf P. Clobazam in drug-resistant patients with complex focal seizures—reports of an open study. In: Hindmarch I, Stonier Pd, Trimble MR, eds. Clobazam: Human Psychopharmacology and Clinical Application. R Soc Med Int Congr Symp Ser No 74:161–171

  98. Allen JW, Jawad S, Oxley J, Trimble M. A long-term study of the efficacy of clobazam as an antiepileptic drug. Short report. In: Hindmarch I, Stonier Pd, Trimble MR, eds. Clobazam: Human Psychopharmacology and Clinical Application. R Soc Med Int Congr Symp Ser No 74:139–140

  99. Shimizu H, Abe J, Futagi Y, et al. Antiepileptic effects of clobazam in children. Brain Dev 1982;4: 57–62.

    PubMed  CAS  Google Scholar 

  100. Martin AA. Clobazam in resistant epilepsy—long term study. In: Hindmarch I, Stonier PD, Trimble MR, eds. Clobazam: human psychopharmacology and clinical application. R Soc Med Int Congr Symp Ser No 74:137–138

  101. Martin AA. The anti-epileptic effects of clobazam: a long-term study in resistant epilepsy. In: Hindmarch I, Stonier PD, Trimble MR, eds. Clobazam. R Soc Med Int Congr Symp Ser No 43:151–157

  102. Dulac O, Figueroa D, Rey E, Arthuis M. Monotherapy with clobazam in epilepsies in children [in French]. Presse Med 1983;12: 1067–1069.

    PubMed  CAS  Google Scholar 

  103. Plouin P, Jalin C. EEG changes in epileptic children treated with clobazam as monotherapy. In: Hindmarch I, Stonier PD, Trimble MR, eds. Clobazam: human psychopharmacology and clinical application. R Soc Med Int Congr Symp Ser No. 74:191–197

  104. Singh A, Guberman AH, Boisvert D. Clobazam in long-term epilepsy treatment: sustained responders versus those developing tolerance. Epilepsia 1995;36: 798–803.

    PubMed  CAS  Article  Google Scholar 

  105. Montenegro MA, Cendes F, Noronha AL, et al. Efficacy of clobazam as add-on therapy in patients with refractory partial epilepsy. Epilepsia 2001;42: 539–542.

    PubMed  CAS  Article  Google Scholar 

  106. Michelucci R, Tassinari CA. Benzodiazepines: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs. 5th ed. Philadelphia, PA: Lippincott, Williams, & Wilkins; 2002: 215–223.

    Google Scholar 

  107. Bawden HN, Camfield CS, Camfield PR, et al. The cognitive and behavioural effects of clobazam and standard monotherapy are comparable. Canadian Study Group for Childhood Epilepsy. Epilepsy Res 1999;33: 133–143.

    PubMed  CAS  Article  Google Scholar 

  108. Cocks A, Critchley EMR, Hayward HW, Thomas D. The effects of clobazam on the blood levels of sodium valproate. Clobazam: human psychopharmacology and clinical applications. R Soc Med Int Congr Symp Ser No 74:155–157.

  109. Theis JG, Koren G, Daneman R, et al. Interactions of clobazam with conventional antiepileptics in children. J Child Neurol 1997;12: 208–213.

    PubMed  CAS  Article  Google Scholar 

Download references

Author information

Affiliations

  1. Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, 85013-4496, Phoenix, Arizona

    Yu-tze Ng

  2. Ovation Pharmaceuticals, Four Parkway North, 60015, Deerfield, IL

    Stephen D. Collins

Authors
  1. Yu-tze Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen D. Collins
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen D. Collins.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ng, Yt., Collins, S.D. Clobazam. Neurotherapeutics 4, 138–144 (2007). https://doi.org/10.1016/j.nurt.2006.11.002

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1016/j.nurt.2006.11.002

Key Words

  • Catastrophic childhood epilepsy
  • refractory epilepsy
  • treatment resistant epilepsy
  • epilepsy treatment
  • Lennox-Gastaut syndrome
  • clobazam